Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Nevro, CV Sciences, and Lannett and Encourages Investors to Contact the Firm
NEW YORK, Oct. 03, 2018 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Nevro Corp., CV Sciences, Inc., and Lannett Company, Inc. Stockholders have until the deadlines listed below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
Nevro Corp. (NYSE: NVRO)
Class Period: January 8, 2018 - July 12, 2018
Lead Plaintiff Deadline: October 22, 2018
The Complaint alleges that, throughout the Class Period, defendants made false and/or misleading statements, as well as failed to disclose material adverse facts about the company’s business, operations, and the proprietary nature of the company’s principal products. Specifically, defendants allegedly made false and/or misleading statements and/or failed to disclose: (1) that Nevro had engaged in a fraudulent scheme by using protected confidential and proprietary trade secrets and stolen documents from its competitors to develop and enhance the company’s Senza systems; (2) that as a result, the company’s Senza systems were not “novel” or “proprietary”; (3) that these practices caused the company to be vulnerable to increased litigation expenses and adverse legal and regulatory action; (4) that, as a result, Nevro’s U.S. sales growth was not sustainable; and (5) that, as a result of the foregoing, defendants’ statements about Nevro’s business, operations, and prospects, were materially false and/or misleading and/or lacked a reasonable basis.
To learn more about the Nevro class action go to: https://bespc.com/nevro/.
CV Sciences, Inc. (Other OTC: CVSI)
Class Period: June 19, 2018 - August 20, 2018
Lead Plaintiff Deadline: October 23, 2018
The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements, as well as failed to disclose material adverse facts about the company’s business, operations, and prospects. Specifically, defendants failed to disclose that the company’s Patent #15/426,617: (1) received a non-final rejection from the USPTO on April 27, 2017; (2) a final rejection from the USPTO on December 14, 2017; and (3) as a result of the foregoing, defendants’ statements about CV Sciences’ business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis.
To learn more about the CV Sciences class action go to: https://bespc.com/cvsi/.
Lannett Company, Inc. (NYSE: LCI)
Class Period: February 7, 2018 - August 17, 2018
Lead Plaintiff Deadline: October 26, 2018
The Complaint alleges that throughout the Class Period, defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company’s business, operations, and prospects. Specifically, defendants failed to disclose that: (1) Lannett faced a substantial risk of the loss of its exclusivity agreement with JSP; (2) accordingly, Lannett’s reported revenues were unsustainable, and (3) as a result, Lannett’s public statements were materially false and misleading at all relevant times.
To learn more about the Lannett class action go to: http://bespc.com/lannett/.
Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information about Bragar Eagel & Squire, P.C. please go to www.bespc.com.
Contacts
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Melissa Fortunato, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
![](https://www.einpresswire.com/tracking/article.gif?t=2&a=Lw2UVkeDcD2Gw3QN&i=WhKPqnG1ID16uj22)